International Research Journal of Human Resource and Social Sciences
ISSN(O): (2349-4085) ISSN(P): (2394-4218)
Impact Factor 6.924 Volume 9, Issue 11, November 2022
Website- www.aarf.asia, **Email** : editoraarf@gmail.com

"MUTATION PROFILING AND CHARACTERIZATION OF MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS (MTB)"

MONIKA BHILWARE
Research Scholar, Sunrire University, Alwar Rajasthan

DR. VISHAL KUMAR CHIMPA
Research Supervisor, Sunrire University, Alwar Rajasthan

ABSTRACT

Multidrug-resistant Mycobacterium tuberculosis (MTB) poses a significant global health threat, with increasing incidence and limited treatment options. Understanding the underlying genetic mutations and molecular mechanisms associated with multidrug resistance is crucial for developing effective diagnostic tools and designing targeted therapies. This research paper aims to provide an in-depth analysis of mutation profiling and characterization of multidrug-resistant MTB strains, highlighting the importance of genomic studies in combating this deadly pathogen.

Keywords: -MTB, RIF, Drugs, Characterization, Health.

I. INTRODUCTION

Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) remains a significant global health concern, responsible for millions of deaths each year. The emergence and spread of multidrug-resistant strains of MTB (MDR-MTB) have further exacerbated the TB crisis, posing immense challenges to its control and treatment. Multidrug-resistant TB is defined as a form of TB that is resistant to at least two of the most potent anti-TB drugs, namely rifampicin (RIF) and isoniazid (INH).

Understanding the underlying genetic mutations and molecular mechanisms associated with multidrug resistance is essential for effective disease management and the development of targeted interventions. Mutation profiling and characterization of MDR-MTB strains have

emerged as vital tools in unraveling the genetic basis of drug resistance, enabling the design of improved diagnostic approaches and the identification of novel therapeutic targets.

II. MOLECULAR BASIS OF DRUG RESISTANCE IN MTB

Overview of Mycobacterium tuberculosis

Mycobacterium tuberculosis is an aerobic, acid-fast bacterium responsible for the infectious disease tuberculosis (TB). It primarily affects the lungs but can also affect other organs and tissues. The complex cell wall composition of MTB contributes to its ability to persist in the host and resist the actions of antimicrobial agents. This resilience is further amplified by the bacterium's genetic variability, which allows it to adapt to different environments and develop resistance to drugs.

Mechanisms of Drug Resistance

- **Mutations in Drug Target Genes**

One of the primary mechanisms through which MTB develops drug resistance is by acquiring mutations in genes encoding drug targets. These mutations alter the structure or function of the target protein, reducing or abolishing the binding affinity of the drug. For example, mutations in the rpoB gene, encoding the RNA polymerase β-subunit, confer resistance to rifampicin, a critical first-line anti-TB drug. Similarly, mutations in the katG gene, encoding the enzyme catalase-peroxidase, can result in isoniazid resistance.

- **Efflux Pumps and Transporter Systems**

Efflux pumps and transporter systems play a significant role in drug resistance by actively extruding drugs from the bacterial cell, preventing their accumulation and effectiveness. In MTB, efflux pumps belonging to the ATP-binding cassette (ABC) and resistance-nodulation-division (RND) superfamilies have been implicated in drug resistance. These pumps can recognize and pump out a wide range of antimicrobial agents, reducing their intracellular concentrations and rendering them less effective.

- **Biochemical Pathways and Metabolism**

Alterations in biochemical pathways and metabolic processes can also contribute to drug resistance in MTB. Mutations in genes involved in the synthesis or activation of drug metabolizing enzymes, such as the katG gene for isoniazid activation, can reduce or disrupt the bactericidal action of drugs. Changes in metabolic pathways can affect the uptake, activation, or inactivation of drugs, allowing MTB to bypass the inhibitory effects of antimicrobial agents.

- **Other Contributing Factors**

In addition to genetic mutations, other factors can influence drug resistance in MTB. These include epigenetic modifications, such as DNA methylation, which can alter gene expression patterns and contribute to drug resistance. Phenotypic changes, such as alterations in cell wall permeability or the presence of drug-inactivating enzymes, can also play a role in drug resistance. Furthermore, the presence of persister cells within MTB populations, which are dormant and highly tolerant to antimicrobial agents, can contribute to treatment failure and relapse.Understanding the molecular mechanisms underlying drug resistance in MTB is essential for several reasons. First, it helps in the development of molecular diagnostic tools that can rapidly detect drug resistance-associated mutations. Second, it aids in the design of novel therapeutic strategies targeting specific drug resistance mechanisms. Finally, it provides insights into the evolution and spread of drug-resistant strains, guiding surveillance efforts and infection control measures.In the following sections, we will delve deeper into the methods used for mutation profiling in MTB, the identification of mutational hotspots and resistance-associated genes, the genomic epidemiology of multidrug-resistant MTB, and the functional characterization of resistance mechanisms, all of which contribute to a comprehensive understanding of drug resistance in this deadly pathogen.

III. METHODS FOR MUTATION PROFILING

Mutation profiling plays a crucial role in identifying genetic alterations responsible for drug resistance in Mycobacterium tuberculosis (MTB). Various methods and technologies have been employed to analyze the genome of MTB strains, enabling the detection and characterization of mutations associated with drug resistance.

Whole Genome Sequencing (WGS)

Whole genome sequencing is a powerful approach that involves determining the complete DNA sequence of an organism's genome. WGS provides a comprehensive view of the genetic variations present in the MTB genome, including single nucleotide polymorphisms (SNPs), insertions, deletions, and structural variations. It allows for the identification of drug resistance-associated mutations in known target genes as well as the discovery of novel mutations that confer resistance. WGS can be performed using next-generation sequencing (NGS) technologies, which offer high-throughput sequencing with faster turnaround times and lower costs compared to traditional Sanger sequencing.

Next-Generation Sequencing (NGS)

Next-generation sequencing platforms have revolutionized the field of genomics by enabling rapid and cost-effective sequencing of large numbers of DNA fragments. NGS technologies, such as Illumina sequencing and Ion Torrent sequencing, have been widely adopted for mutation

profiling in MTB. These methods generate millions of short DNA reads, which are then aligned to a reference genome to identify sequence variations, including drug resistance-associated mutations. NGS-based approaches are particularly useful for screening large numbers of clinical MTB isolates and tracking the spread of drug-resistant strains.

Polymerase Chain Reaction (PCR) and Sequencing Techniques

PCR-based methods are commonly employed for targeted mutation profiling in MTB. Various PCR assays, such as allele-specific PCR, multiplex PCR, and real-time PCR, have been developed to detect specific mutations associated with drug resistance. These techniques rely on the amplification of the target DNA region containing the mutation, followed by subsequent analysis through DNA sequencing or probe-based detection methods. PCR-based approaches are valuable for their sensitivity, simplicity, and rapid turnaround time, making them suitable for diagnostic applications.

Bioinformatics Tools for Data Analysis

The analysis of mutation profiling data requires robust bioinformatics tools and pipelines. Bioinformatics algorithms are employed to process sequencing data, align the reads to a reference genome, and identify genetic variations. Variant calling algorithms, such as GATK (Genome Analysis Toolkit) and SAMtools, are commonly used to detect SNPs, insertions, and deletions. Several specialized bioinformatics tools and databases have been developed specifically for MTB mutation profiling, including TB-Profiler, Mykrobe Predictor TB, and TBVar, which provide comprehensive annotation and interpretation of drug resistance-associated mutations.

IV. MUTATIONAL HOTSPOTS AND RESISTANCE-ASSOCIATED GENES

Mutational hotspots are specific regions within the genome of Mycobacterium tuberculosis (MTB) that are prone to acquiring mutations associated with drug resistance. These hotspots often correspond to genes involved in the action or metabolism of anti-TB drugs. By identifying mutational hotspots and characterizing resistance-associated genes, researchers gain insights into the genetic mechanisms underlying drug resistance in MTB.

Mutations in the Rifampicin (RIF) Resistance-Determining Region

Rifampicin is a potent first-line anti-TB drug that targets the RNA polymerase β-subunit encoded by the rpoB gene. Mutations in the RIF resistance-determining region (RRDR) of the rpoB gene account for the majority of rifampicin resistance in MTB. The RRDR spans a specific region of the rpoB gene, including codons 507 to 533, where mutations confer resistance by altering the binding site of rifampicin to the RNA polymerase. Common mutations in the RRDR include substitutions at codons 526, 531, and 516, which result in reduced affinity for rifampicin.

Isoniazid (INH) Resistance-Associated Mutations

Isoniazid is a key first-line drug used in the treatment of TB, and resistance to isoniazid often arises due to mutations in several genes. The most common resistance-associated mutations occur in the katG gene, which encodes the enzyme catalase-peroxidase responsible for activating isoniazid. Mutations in codon 315 of the katG gene are particularly prevalent and result in reduced activation of isoniazid. Additionally, mutations in the inhA gene, which encodes the target of isoniazid, the enoyl-acyl carrier protein reductase, can also confer resistance by reducing the binding affinity of the drug.

Fluoroquinolone (FQ) Resistance-Associated Mutations

Fluoroquinolones, such as moxifloxacin and levofloxacin, are second-line drugs used to treat drug-resistant TB. Resistance to fluoroquinolones primarily arises due to mutations in genes encoding DNA gyrase (gyrA) and DNA topoisomerase IV (parC). Mutations in specific regions of the gyrA gene, particularly at codons 90, 91, and 94, are frequently associated with fluoroquinolone resistance in MTB. Mutations in the parC gene have also been reported, although less frequently. These mutations alter the drug-binding sites and reduce the susceptibility of MTB to fluoroquinolones.

Other Drug Resistance-Associated Mutations

In addition to the aforementioned genes, mutations in other genes have been associated with drug resistance in MTB. For example, ethambutol resistance is often associated with mutations in the embB gene, which encodes the arabinosyltransferase involved in cell wall biosynthesis. Streptomycin resistance has been linked to mutations in the rpsL and rrs genes, which encode components of the ribosome. Additional resistance-associated mutations have been identified in genes such as pncA (pyrazinamide resistance), ethA (ethionamide resistance), and inhA promoter region (low-level isoniazid resistance).

V. CONCLUSION

In conclusion, mutation profiling and characterization of multidrug-resistant Mycobacterium tuberculosis (MTB) strains play a crucial role in understanding the molecular basis of drug resistance. Through various methods such as whole genome sequencing, next-generation sequencing, polymerase chain reaction (PCR), and bioinformatics analysis, researchers can identify mutational hotspots and resistance-associated genes that contribute to the emergence and spread of drug-resistant TB.

The molecular mechanisms underlying drug resistance in MTB involve genetic mutations in drug target genes, efflux pumps and transporter systems, alterations in biochemical pathways and metabolism, as well as other contributing factors such as epigenetic modifications and

phenotypic changes. These mechanisms collectively contribute to reduced drug efficacy and treatment failure in multidrug-resistant TB.

By investigating mutational hotspots, such as the Rifampicin Resistance-Determining Region (RRDR) in the rpoB gene and the isoniazid resistance-associated mutations in the katG and inhA genes, researchers can gain insights into the specific genetic changes responsible for drug resistance. Similarly, identifying mutations in genes involved in fluoroquinolone resistance, such as gyrA and parC, helps in understanding the resistance mechanisms against this class of drugs.

The knowledge gained from mutation profiling and characterization of drug-resistant MTB strains has significant implications for TB control and treatment. It aids in the development of molecular diagnostic tools that can accurately and rapidly detect drug resistance, allowing for early identification of resistant strains and tailored treatment strategies. Moreover, understanding the mutational landscape of drug resistance helps in the identification of new drug targets and the design of novel therapeutic approaches to combat multidrug-resistant TB.

However, challenges remain in mutation profiling, including the need for standardization of methodologies, access to high-quality sequencing technologies, and comprehensive databases for mutation annotation and interpretation. Additionally, the continuous monitoring of drug resistance patterns and the global spread of resistant strains is crucial for effective TB control and prevention.

In conclusion, mutation profiling and characterization of multidrug-resistant MTB strains provide valuable insights into the genetic mechanisms driving drug resistance. This knowledge contributes to the development of improved diagnostics, targeted therapies, and global strategies to combat the global health crisis posed by multidrug-resistant TB. Continued research in this field is essential for the development of effective interventions and ultimately the eradication of TB.

REFERENCES

1. Farhat MR, Jacobson KR, Franke MF, et al. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet. 2013;45(10):1183-1189.

2. Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. EurRespir J. 2017;50(6):1701354.

3. Rigouts L, Coeck N, Gumusboga M, et al. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J AntimicrobChemother. 2016;71(2):314-323.

4. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF Ultra for the diagnosis of pulmonary tuberculosis in children: a multicentre, retrospective cohort study. Lancet Infect Dis. 2018;18(11):1305-1313.

5. Zignol M, Dean AS, Falzon D, et al. Twenty years of global surveillance of antituberculosis-drug resistance. N Engl J Med. 2016;375(11):1081-1089.

6. Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15(10):1193-1202.

7. Zhang H, Li D, Zhao L, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet. 2013;45(10):1255-1260.